Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Solvonis Therapeutics ( (GB:SVNS) ) is now available.
Solvonis Therapeutics reported broad progress across its CNS pipeline as it heads into what it describes as a catalyst-rich 2026, highlighting advancement of its lead alcohol use disorder (AUD) and PTSD programmes alongside AI-driven discovery efforts. Lead candidate SVN-001 is moving through a potentially pivotal Phase 3 trial for severe AUD in a large, underserved UK and EU population, while SVN-002, an esketamine oral thin film for moderate-to-severe AUD, is being prepared for a U.S. Phase 2b trial via an FDA 505(b)(2) pathway that could materially reduce development time and cost. The company also secured external validation for its AI-enabled platform with SVN-015’s acceptance into the U.S. National Institute on Drug Abuse’s Addiction Treatment Discovery Program, which brings NIDA-funded preclinical work and potential access to further non-dilutive NIH development funding for stimulant use disorder. Meanwhile, PTSD candidate SVN-SDN-14 is nearing lead selection ahead of IND-enabling studies, and Solvonis says the integration of Awakn Life Sciences earlier in 2025 has created a more diversified CNS platform, positioning the group with multiple regulatory, preclinical and partnering milestones that could enhance both its industry standing in addiction psychiatry and its long-term value proposition for shareholders.
More about Solvonis Therapeutics
Solvonis Therapeutics plc is a London-headquartered, LSE-listed emerging biopharmaceutical company focused on developing novel small‑molecule therapeutics for high-burden central nervous system disorders. The company’s differentiated pipeline spans addiction, psychiatry and neurology, led by alcohol use disorder and post-traumatic stress disorder programmes, and combines repurposed and novel compounds supported by an AI-enabled discovery platform and a capital-efficient, partnership-oriented development model.
Average Trading Volume: 46,384,260
Technical Sentiment Signal: Sell
Current Market Cap: £19.06M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.